Dr. Anissa Abi-Dargham, M.D

NPI: 1376769729
Total Payments
$98,961
2024 Payments
$11,275
Companies
9
Transactions
64

Payment Breakdown by Category

Consulting$78,769 (79.6%)
Other$16,859 (17.0%)
Travel$2,140 (2.2%)
Food & Beverage$1,192 (1.2%)

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $78,769 26 79.6%
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $16,859 9 17.0%
Travel and Lodging $2,140 11 2.2%
Food and Beverage $1,192 18 1.2%

Top Paying Companies

Company Total Records Latest Year
Sunovion Pharmaceuticals Inc. $28,930 10 $0 (2022)
Otsuka Pharmaceutical Development & Commercialization, Inc. $20,492 19 $0 (2021)
ABBVIE INC. $11,623 12 $0 (2024)
Otsuka America Pharmaceutical, Inc. $10,673 8 $0 (2018)
Merck Sharp & Dohme LLC $10,500 7 $0 (2024)
Sumitomo Pharma America, Inc. $6,280 2 $0 (2023)
Boehringer Ingelheim Pharma GmbH & Co.KG $3,990 1 $0 (2022)
F. Hoffmann-La Roche AG $3,320 1 $0 (2022)
Neurocrine Biosciences, Inc. $3,153 4 $0 (2023)

Payment History by Year

Year Amount Transactions Top Company
2024 $11,275 2 ABBVIE INC. ($9,775)
2023 $12,315 16 Sumitomo Pharma America, Inc. ($6,280)
2022 $28,806 12 Sunovion Pharmaceuticals Inc. ($16,718)
2021 $15,497 7 Sunovion Pharmaceuticals Inc. ($12,212)
2020 $17,961 14 Otsuka Pharmaceutical Development & Commercialization, Inc. ($15,899)
2019 $2,418 4 Otsuka Pharmaceutical Development & Commercialization, Inc. ($2,418)
2018 $2,172 2 Otsuka America Pharmaceutical, Inc. ($2,172)
2017 $8,517 7 Otsuka America Pharmaceutical, Inc. ($8,501)

All Payment Transactions

64 individual payment records from CMS Open Payments — Page 1 of 3

Date Company Product Nature Form Amount Type
01/29/2024 Merck Sharp & Dohme LLC Consulting Fee Cash or cash equivalent $1,500.00 General
Category: NEUROSCIENCE
01/10/2024 ABBVIE INC. Consulting Fee Cash or cash equivalent $9,775.00 General
11/21/2023 AbbVie Inc. Travel and Lodging In-kind items and services $492.94 General
11/21/2023 AbbVie Inc. Travel and Lodging In-kind items and services $129.18 General
11/21/2023 AbbVie Inc. Food and Beverage In-kind items and services $59.80 General
11/20/2023 AbbVie Inc. Travel and Lodging In-kind items and services $398.49 General
11/20/2023 AbbVie Inc. Food and Beverage In-kind items and services $114.40 General
11/20/2023 AbbVie Inc. Food and Beverage In-kind items and services $59.80 General
11/20/2023 AbbVie Inc. Food and Beverage In-kind items and services $10.40 General
11/20/2023 AbbVie Inc. Food and Beverage In-kind items and services $5.65 General
11/20/2023 AbbVie Inc. Food and Beverage In-kind items and services $5.53 General
11/19/2023 AbbVie Inc. Travel and Lodging In-kind items and services $398.49 General
11/19/2023 AbbVie Inc. Travel and Lodging In-kind items and services $173.18 General
09/21/2023 Sumitomo Pharma America, Inc. Consulting Fee Cash or cash equivalent $3,280.00 General
07/05/2023 Merck Sharp & Dohme LLC Consulting Fee Cash or cash equivalent $1,500.00 General
Category: NEUROSCIENCE
05/16/2023 Sumitomo Pharma America, Inc. Consulting Fee Cash or cash equivalent $3,000.00 General
01/05/2023 Neurocrine Biosciences, Inc. Consulting Fee Cash or cash equivalent $1,000.00 General
01/04/2023 Merck Sharp & Dohme LLC Consulting Fee Cash or cash equivalent $1,687.50 General
Category: NEUROSCIENCE
12/15/2022 Sunovion Pharmaceuticals Inc. Consulting Fee Cash or cash equivalent $3,280.00 General
12/15/2022 Sunovion Pharmaceuticals Inc. Consulting Fee Cash or cash equivalent $525.00 General
12/05/2022 Neurocrine Biosciences, Inc. Food and Beverage In-kind items and services $152.50 General
10/17/2022 Sunovion Pharmaceuticals Inc. Food and Beverage In-kind items and services $64.41 General
10/01/2022 F. Hoffmann-La Roche AG Consulting Fee Cash or cash equivalent $3,320.46 General
09/29/2022 Sunovion Pharmaceuticals Inc. Consulting Fee Cash or cash equivalent $9,569.07 General
07/15/2022 Merck Sharp & Dohme LLC Consulting Fee Cash or cash equivalent $1,500.00 General
Category: NEUROSCIENCE

About Dr. Anissa Abi-Dargham, M.D

Dr. Anissa Abi-Dargham, M.D is a Psychiatry healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/17/2007. The National Provider Identifier (NPI) number assigned to this provider is 1376769729.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Anissa Abi-Dargham, M.D has received a total of $98,961 in payments from pharmaceutical and medical device companies, with $11,275 received in 2024. These payments were reported across 64 transactions from 9 companies. The most common payment nature is "Consulting Fee" ($78,769).

Practice Information

  • Specialty Psychiatry
  • Location New York, NY
  • Active Since 04/17/2007
  • Last Updated 07/08/2007
  • Taxonomy Code 2084P0800X
  • Entity Type Individual
  • Practice Solo Practitioner
  • NPI Number 1376769729

Products in Payments

  • REXULTI (Drug) $10,901
  • MK-8189 (Drug) $2,063

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Psychiatry Doctors in New York